CMIC Holdings Co Ltd (2309)

CMIC HOLDINGS Co., Ltd. provides pharmaceutical development services in Japan. The company offers clinical trial services, including audit and quality assurance, clinical operations and trials, data management, clinical caretaker, patient recruitment, pharmacovigilance, project management, and statistical analysis; and clinical site network, CMC, drug development, health economics and outcome research, market entry/out-licensing, medical devices and in vitro diagnostic consulting, medical writing, national health insurance/drug pricing, and product life cycle management consulting services. It also provides development and manufacturing services, including commercial supply, contract development and manufacturing, investigational product manufacturing, packaging and labeling, release and stability tests, and technology transfer, as well as formulation development services; and laboratory services, such as bioanalysis and GLP analysis, biomarkers, CMC and GMP analysis, large molecule, oligonucleotides, small molecule, and toxicity, as well as efficacy and safety pharmacology, in vitro and in vivo, and non-clinical studies. In addition, the company offers marketing authorization holder and medical affair services; patient and healthcare services, such as call center, drug adherence support program, harmo, Helc, and prescription drug database services, as well as SelCheck, a self-test kit; and post-marketing surveillance, self-inspection, regulatory affairs consulting, regulatory submissions and correspondence, sales and marketing, clinical research coordinating, clinical site administration, and site management services. The company was incorporated in 1985 and is headquartered in Tokyo, Japan.CMIC HOLDINGS Co., Ltd. operates as a subsidiary of SORA Corporation.